Michael Dickinson, MD
Advanced Heart Failure and Transplant Cardiology · Grand Rapids, MINPI 1942289798
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $70,850 of the $80,055 with a category attached, or 88.5%. Boehringer Ingelheim accounts for 69.7% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $39,872, more than ten times the $746 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $526.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$56K
- Lilly USA, LLC$21K
- Abbott$2K
- Abiomed$394
- Medtronic$336
- Pfizer$168
- plus $1K from 15 others
Across 47 payments — averaging $540.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$18K
- Abbott$7K
What the payments were for
- Speaking & faculty fees$70,85089%
- Travel & lodging$3,2534%
- Food & beverage$5,9527%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 63 | $55,833 |
| Lilly USA, LLC | 21 | $20,648 |
| Abbott | 18 | $1,574 |
| Abiomed | 6 | $394 |
| Medtronic | 5 | $336 |
| Pfizer | 10 | $168 |
| ZOLL Respicardia, Inc. | 1 | $160 |
| Novartis | 9 | $148 |
| Cvrx, Inc. | 1 | $132 |
| Actelion Pharmaceuticals US, Inc. | 1 | $130 |
| Chiesi USA, Inc. | 1 | $129 |
| Bridgebio Pharma, Inc. | 2 | $122 |
| AstraZeneca | 4 | $71 |
| Alnylam Pharmaceuticals Inc. | 1 | $32 |
| Scpharmaceuticals Inc. | 2 | $31 |
| Amgen | 2 | $30 |
| Irhythm Technologies, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| AbbVie | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$64,017
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$597
- Impella$348
- HeartWare HVAD$275
- HeartMate 3 Left Ventricular Assist Device$256
- CARDIOMEMS$166
- CardioMEMS HF System$160
- remede System$160
- Barostim Neo System$132
- UPTRAVI$130
- OPSUMIT$130
- ELFABRIO$129
- Attruby$109
How this compares
$80,055 in reported general payments places this provider in the 90th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
See all advanced heart failure and transplant cardiology providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 226 | $5,234,198 |
| EntrestoSacubitril/Valsartan | 453 | $503,098 |
| JardianceEmpagliflozin | 313 | $322,196 |
| EliquisApixaban | 255 | $292,377 |
| FarxigaDapagliflozin Propanediol | 195 | $195,071 |
| XareltoRivaroxaban | 88 | $106,824 |
| OzempicSemaglutide | 54 | $54,041 |
| CorlanorIvabradine Hcl | 38 | $35,126 |
| MounjaroTirzepatide | 18 | $18,210 |
| Metoprolol Succinate | 550 | $15,320 |
| Torsemide | 395 | $10,744 |
| Midodrine Hcl | 86 | $10,400 |
| DapagliflozinDapagliflozin Propanediol | 13 | $10,113 |
| BrilintaTicagrelor | 16 | $9,047 |
| Spironolactone | 695 | $8,464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $168 | $5,526,575481 claims |
| NovartisEntresto | $148 | $503,098453 claims |
| Boehringer IngelheimJardiance | $55,833 | $322,196313 claims |
| AstraZenecaFarxiga, Brilinta | $71 | $204,117211 claims |
| AmgenCorlanor | $30 | $35,12638 claims |
| Lilly USA, LLCMounjaro | $20,648 | $18,21018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
Other advanced heart failure and transplant cardiology in Grand Rapids
- David FerminGrand Rapids$105K
- Sangjin LeeGrand Rapids$25K
- Matthew GonzalezGrand Rapids$22K
- Renzo Loyaga-RendonGrand Rapids$5K
- Ryan GrayburnGrand Rapids$4K
- Milena JaniGrand Rapids$3K
- Jennifer CowgerDetroit$165K
- Thomas CascinoAnn Arbor$39K
- Keith AaronsonAnn Arbor$22K
- Waleed Al-DarziDetroit$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.